KDM1A and acute myeloid leukemia: Likewise, Schenk et al. showed that LSD1 inhibition resensitized AML cell lines or primary samples of non-acute promyelocytic leukemia AML to ATRA treatment by re-activating the all-trans-retinoic acid differentiation pathway, a therapeutic regimen that is usually ineffective in these types of leukemias [86].